Sanjeev Thohan is a Senior Director of Preclinical Safety at Xeris Pharmaceuticals. He holds MS and PhD degrees in Pharmacology and Toxicology from the University of Arizona and University of Maryland with concentrations in interspecies drug metabolism mechanisms, bioactivation, and systems toxicology.
Sanjeev has extensive experience in Oncology drug discovery, biomarker identification, companion diagnostic identification and drug development from his time at Novartis and Exelixis. He was a Senior Research Fellow in Preclinical/Translational Sciences at the Novartis Institutes for BioMedical Research (NIBR) in the Oncology, Anti-infectives and Cardiovascular medicines therapeutic areas.
Sanjeev has held positions in increasing responsibility covering disciplines of ADME, DMPK and TOX areas of preclinical research with small and large organizations (Walter Reed Army Institute for Research, Covance, AstraZeneca, ViroPharma, Exelixis, Novartis and Xeris).
Sanjeev continues to be a contributing member of several national/international scientific societies. He actively serves on the advisory boards for several entrepreneurial corporations including an NIH collaborative platform with the centers for Advancing Innovation. He serves as a subject matter expert in the drug and device arenas as well as allied technology applications for medicine.